Sign up to save your podcasts
Or
Share What About The Pfizer CoVid Pill?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What About The Pfizer CoVid Pill?
Vidcast: https://youtu.be/SZG20jo_yII
You’ve heard about it on TV and radio, and the headlines trumpet something like “Pfizer says its CoVid pill is near 90% effective.” Well….. let’s take a closer look at the available data
Pfizer’s Paxlovid is combination therapy including a novel protease inhibitor nirmatrelvir or PF-07321332 and an antiviral cytochrome inhibitor Ritonavir. When these two drugs in separate pills are taken every 12 hours for 5 days beginning within the first days after symptom onset, they prevent hospitalizations and deaths for high-risk persons by 89%. High risk would be older patients and those with complicating medical problems such as diabetes and cardiovascular disease. This according to a new analysis of 2200 participants. An earlier study showed the Paxlovid drug combo to be 70% effective for those in a standard risk category.
This is exciting news, but there is a sketchy side. First, all the information we see, hear, and read only comes from Pfizer press releases not from their actual submission to the FDA for the Emergency Use Authorization. As a medical journalist with NIH research experience, I want to see the actual data.
Then there is what we don’t know about the Pfizer CoVid pill. What will suppressing rather than preventing CoVid do regarding long CoVid? Will the pill prevent the lingering symptoms of fatigue, fogginess, and chronic aching? Will Paxlovid prevent CoVid from damaging your vital organs including your lungs with chronic scarring and slow suffocation, your heart with myocarditis and congestive heart failure, your brain with encephalitis, your kidneys with renal failure, your liver with cirrhosis, and your pancreas with diabetes.
The better strategy is to avoid contracting the many variants of CoVid in the first place by maintaining immunity against CoVid by vaccination and timely boosting, by strategic and sometimes double masking, and by avoiding virus aerosols indoors and in dense crowds.
https://bit.ly/321lkyS
https://sites.dartmouth.edu/dujs/2021/12/08/pfizers-new-covid-19-drug-paxlovid/
#CoVid #pfizer #proteaseinhibitor #paxlovid #bigpharma
CoVid, pfizer, proteaseinhibitor, paxlovid, bigpharma
View all episodes
By Howard G. Smith MD, AM
Vidcast: https://youtu.be/SZG20jo_yII
You’ve heard about it on TV and radio, and the headlines trumpet something like “Pfizer says its CoVid pill is near 90% effective.” Well….. let’s take a closer look at the available data
Pfizer’s Paxlovid is combination therapy including a novel protease inhibitor nirmatrelvir or PF-07321332 and an antiviral cytochrome inhibitor Ritonavir. When these two drugs in separate pills are taken every 12 hours for 5 days beginning within the first days after symptom onset, they prevent hospitalizations and deaths for high-risk persons by 89%. High risk would be older patients and those with complicating medical problems such as diabetes and cardiovascular disease. This according to a new analysis of 2200 participants. An earlier study showed the Paxlovid drug combo to be 70% effective for those in a standard risk category.
This is exciting news, but there is a sketchy side. First, all the information we see, hear, and read only comes from Pfizer press releases not from their actual submission to the FDA for the Emergency Use Authorization. As a medical journalist with NIH research experience, I want to see the actual data.
Then there is what we don’t know about the Pfizer CoVid pill. What will suppressing rather than preventing CoVid do regarding long CoVid? Will the pill prevent the lingering symptoms of fatigue, fogginess, and chronic aching? Will Paxlovid prevent CoVid from damaging your vital organs including your lungs with chronic scarring and slow suffocation, your heart with myocarditis and congestive heart failure, your brain with encephalitis, your kidneys with renal failure, your liver with cirrhosis, and your pancreas with diabetes.
The better strategy is to avoid contracting the many variants of CoVid in the first place by maintaining immunity against CoVid by vaccination and timely boosting, by strategic and sometimes double masking, and by avoiding virus aerosols indoors and in dense crowds.
https://bit.ly/321lkyS
https://sites.dartmouth.edu/dujs/2021/12/08/pfizers-new-covid-19-drug-paxlovid/
#CoVid #pfizer #proteaseinhibitor #paxlovid #bigpharma
CoVid, pfizer, proteaseinhibitor, paxlovid, bigpharma